High grade glioma + brainstem glioma Highly agressive tumours
Nimotuzumab and radiotherapy in children and adolescents with brain stem glioma: Preliminary results...
1
Nimotuzumab and radiotherapy in children and adolescents with brain stem glioma: Preliminary results from a Phase II study. T. Crombet 1 , R. Cabanas 2 , J. Alert 3 , J. Valdés 2 , M.C. González 2 , J.L. Pedrayes 2 , M. Ríos 4 , T. Leyva 4 , R. Herrera 4 , M. Avila 4 1 Center of Molecular Immunology, Clinical Immunology Department, Havana, Cuba. 2 Juan Manuel Marquez Hospital, Oncohematology, Havana, Cuba. 3 National Institute of Oncology, Radiotherapy, Havana, Cuba. 4 Juan Manuel Marquez Hospital, Neurosurgery, Havana, Cuba. Background: Several EGFR-targeting products have been approved worldwide for the treatment of different tumor localizations. Nimotuzumab is a humanized, anti-EGFR monoclonal antibody registered in several countries for the treatment of advanced head and neck cancer and recurrent glioma. A Phase II, open label clinical trial was designed to evaluate the progression-free survival rate at 6 months, as well as the overall survival, of children and adolescents newly diagnosed with brain stem gliomas treated with nimotuzumab in combination with external beam radiotherapy Material and methods: Newly diagnosed patients with clinical and radiological evidence of brain stem tumor, aged between 3 - 18 years, Karnofsky > 40, adequate renal, liver and hematological functions, were eligible. Nimotuzumab was administered at a dose of 150 mg/m 2 weekly for 12 weeks concomitantly with external beam radiotherapy (induction therapy). Treatment consolidation consisted of similar doses of nimotuzumab at a 2- week interval except in cases of significant deterioration of the performance status. Tumor evaluation was performed using MRI every 12 weeks. Results: Ten patients have been enrolled in this study to date. After completing induction therapy, 8 patients were evaluable for response, 7 patients achieved stable disease (SD), while 1 patient progressed. After 24 weeks, 6 patients were evaluable and all of them showed at least disease stabilization. At the 48 week evaluation there were 3 evaluable patients and 2 of them had partial responses. The most frequent adverse event was grade 1-2 mucositis. None of the patients developed skin rash. The study is ongoing and updated results will be presented. Conclusions: Nimotuzumab is safe. Preliminary results suggest efficacy of the humanized anti-EGFR MAb in combination with radiotherapy in children and adolescents newly diagnosed with brain stem glioma. Trial continuation is warranted. Humanized Anti-EGFR MoAb Nimotuzumab (h-R3) Humanized IgG1 K d = 10 –9 M Decreases the cell proliferation in combination with radiotherapy. Inhibits tumor angiogenesis by the reduction of the size of tumor vessels in combination with radiotherapy. Induces apoptosis Reduces the phosphorylation of ERK1/2 alone and in combination with radiotherapy Reduces the number of microsatellites. Reduces the number of radio-resistant CD133 positive cancer stem cells. Induces significant regression of well established glioma xenografts in nude mice. Blocks EGF binding to the EGFR while allowing the active receptor confo rmation Description of patient population Patients with histologically or radiologically verified diagnosis of brain stem glioma, defined as involvement of > 2/3 of the pons on initial MRI, or 2 of 3 of the following symptoms: cranial nerve deficit, long tract signs, ataxia and a onset prior to initial diagnosis < 6 months. Description of study treatment Patients receive nimotuzumab (150 mg/m 2 X 12 weeks) plus RTP (50-60 Gy). Maintenance of 150 mg/m 2 every 14 day until disease progression. Primary endpoint Event free survival rate at 6 months Secondary endpoints Survival benefit Objective response (CR+PR) Duration of response Safety Number of subjects initially planned: 40 Body System Coded Term Active Drug N Constitutional symptoms Hypothermia 1 Paleness 1 Gastrointestinal Mucositis 1 Neurology Seizure 1 Safety Total number of all subjects randomized to date: 11 Gender: 4 males, 7 females Age range: 3-18 years Races: White: 6 Black:5 Safety Overall Response Best response N=8 Complete Response Partial Response 2 Stable Disease 5 Progressive Disease 1 April 2008 July 2008 Nov 2008 Jan 2009 Dec 2007 March 2008 Oct 2008 Conclusions •Nimotuzumab at multiple doses was very well tolerated in combination with radiotherapy in children bearing brain stem glioma. •No skin rash or allergic reactions appeared. •Preliminary results suggest efficacy of the humanized anti-EGFR MAb in combination with radiotherapy in children and adolescents with newly diagnosed brain stem glioma. Patients showing partial response: Patient 03 (GRA) and Patient 04 (RCB) C M
-
Upload
evelyn-bentley -
Category
Documents
-
view
213 -
download
1
Transcript of Nimotuzumab and radiotherapy in children and adolescents with brain stem glioma: Preliminary results...
Nimotuzumab and radiotherapy in children and adolescents with brain stem glioma: Preliminary results from a Phase II study.
T. Crombet1, R. Cabanas2, J. Alert3, J. Valdés2, M.C. González2, J.L. Pedrayes2, M. Ríos4, T. Leyva4, R. Herrera4, M. Avila4
1Center of Molecular Immunology, Clinical Immunology Department, Havana, Cuba. 2Juan Manuel Marquez Hospital, Oncohematology, Havana, Cuba. 3National Institute of Oncology, Radiotherapy, Havana, Cuba. 4Juan Manuel Marquez Hospital, Neurosurgery, Havana, Cuba.
Background: Several EGFR-targeting products have been approved worldwide for the treatment of different tumor localizations. Nimotuzumab is a humanized, anti-EGFR monoclonal antibody registered in several countries for the treatment of advanced head and neck cancer and recurrent glioma. A Phase II, open label clinical trial was designed to evaluate the progression-free survival rate at 6 months, as well as the overall survival, of children and adolescents newly diagnosed with brain stem gliomas treated with nimotuzumab in combination with external beam radiotherapy Material and methods: Newly diagnosed patients with clinical and radiological evidence of brain stem tumor, aged between 3 - 18 years, Karnofsky > 40, adequate renal, liver and hematological functions, were eligible. Nimotuzumab was administered at a dose of 150 mg/m2 weekly for 12 weeks concomitantly with external beam radiotherapy (induction therapy). Treatment consolidation consisted of similar doses of nimotuzumab at a 2-week interval except in cases of significant deterioration of the performance status. Tumor evaluation was performed using MRI every 12 weeks.Results: Ten patients have been enrolled in this study to date. After completing induction therapy, 8 patients were evaluable for response, 7 patients achieved stable disease (SD), while 1 patient progressed. After 24 weeks, 6 patients were evaluable and all of them showed at least disease stabilization. At the 48 week evaluation there were 3 evaluable patients and 2 of them had partial responses. The most frequent adverse event was grade 1-2 mucositis. None of the patients developed skin rash. The study is ongoing and updated results will be presented.Conclusions: Nimotuzumab is safe. Preliminary results suggest efficacy of the humanized anti-EGFR MAb in combination with radiotherapy in children and adolescents newly diagnosed with brain stem glioma. Trial continuation is warranted.
Humanized Anti-EGFR MoAb Nimotuzumab (h-R3)
Humanized IgG1
Kd = 10 –9 M
Decreases the cell proliferation in combination with radiotherapy.Inhibits tumor angiogenesis by the reduction of the size of tumor vessels in combination with radiotherapy.Induces apoptosisReduces the phosphorylation of ERK1/2 alone and in combination with radiotherapyReduces the number of microsatellites.Reduces the number of radio-resistant CD133 positive cancer stem cells.Induces significant regression of well established glioma xenografts in nude mice. Blocks EGF binding to the EGFR while allowing the active receptor conformation
Description of patient population
Patients with histologically or radiologically verified diagnosis of brain stem glioma, defined as involvement of > 2/3 of the pons on initial MRI, or 2 of 3 of the following symptoms: cranial nerve deficit, long tract signs, ataxia and a onset prior to initial diagnosis < 6 months.
Description of study treatment
Patients receive nimotuzumab (150 mg/m2 X 12 weeks) plus RTP (50-60 Gy).Maintenance of 150 mg/m2 every 14 day until disease progression.
Primary endpointEvent free survival rate at 6 months
Secondary endpointsSurvival benefitObjective response (CR+PR)Duration of responseSafety
Number of subjects initially planned: 40
Body System Coded Term
Active DrugN
Constitutional symptomsHypothermia 1Paleness 1GastrointestinalMucositis 1NeurologySeizure 1
Safety
Total number of all subjects randomized to date: 11Gender: 4 males, 7 femalesAge range: 3-18 yearsRaces: White: 6 Black:5
SafetyOverall Response
Best response N=8Complete ResponsePartial Response 2Stable Disease 5Progressive Disease 1
April 2008 July 2008Nov 2008
Jan 2009
Dec 2007 March 2008 Oct 2008
Conclusions
•Nimotuzumab at multiple doses was very well tolerated in combination with radiotherapy in children bearing brain stem glioma.•No skin rash or allergic reactions appeared.•Preliminary results suggest efficacy of the humanized anti-EGFR MAb in combination with radiotherapy in children and adolescents with newly diagnosed brain stem glioma.
Patients showing partial response: Patient 03 (GRA) and Patient 04 (RCB)
C M
